Summary
The efficacy of cefodizime (CDZ) in upper urinary tract infections (UUTI) and complicated lower urinary tract infections (LUTI) was assessed by analysis of the combined results of five clinical trials. Doses of CDZ 1g i.m. daily, 1 × 2 g i.v. or i.m. and 2 × 2 g i.v. were investigated; comparative agents were cefuroxime 3 × 1.5 g and ceftizoxime 1 × 2 g. Median duration of treatment was seven days. A total of 544 patients, 61% of whom had UUTI, entered the studies. Four hundred twenty-two patients were evaluable clinically and 375 bacteriologically. The most frequent pathogen at baseline wasEscherichia coli, followed byProteus mirabilis, Klebsiella spp. andStaphylococcus aureus. Both clinical and bacteriological cure rates were above 90% in all study groups. The dosage of 1 × 2 g CDZ is recommended for the treatment of UUTI and complicated LUTI.
Zusammenfassung
Die kombinierte Analyse der Wirksamkeit von Cefodizim (CDZ) bei Infektionen der oberen Harnwege und komplizierten Infektionen der unteren Harnwege anhand von fünf klinischen Prüfungen umfaßte folgende Dosierungen: CDZ 1 g/d i.m., 1 × 2 g/d i.v. oder i.m. und 2 × 2 g/d i.v., Vergleichssubstanzen: Cefuroxim 3 × 1,5 g, Ceftizoxim 1 × 2 g. Die Behandlungsdauer betrug im Median sieben Tage. Fünfhundertvierundvierzig Patienten wurden in die klinischen Prüfungen aufgenommen, bei 61% davon bestand eine Infektion der oberen Harnwege. Vierhundertzweiundzwanzig Patienten waren klinisch auswertbar, 375 bakteriologisch. Die häufigsten Keime wareEscherichia coli, gefolgt vonProteus mirabilis, Klebsiella spp. undStaphylococcus aureus. Sowohl die klinischen als auch die bakteriologischen Heilungsquoten lagen in allen Dosisgruppen über 90%. Die empfohlene Dosis von CDZ bei Infektionen der oberen Harnwege und bei komplizierten Infektionen der unteren Harnwege beträgt 1 × 2 g/d.
Similar content being viewed by others
References
Knothe, H., Shah, P. M. In vitro activity of cefodizime. Infection 20 (1992) (Suppl. 1) S 3-S 8.
Naber, K. G., Bauernfeind, A., Dietlein, G., Wittenberger, R. Urinary pathogens and bacterial sensitivity in hospitalized urological patients based upon clinical aspects. Scand. J. Urol. Nephrol. 104 (1987) (Suppl. 0) 47–57.
Scully, B. E., Jules, K., Neu, H. C. In vitro activity and β-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin. Antimicrob. Agents Chemother. 23 (1983) 907–913.
Korting, H. C., Schäfer-Korting, M., Maas, L., Klesel, N., Mutschler, E. Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob. Agents Chemother. 31 (1987) 1822–1825.
Hofstetter, A., Knipper, A., Dagrosa, E. E., Klesel, N. Concentration of cefodizime (HR 221), a new cephalosporin, in urological tissues. In:Ishigami, J. (ed.): Recent advances in chemotherapy, antimicrobial section 2. University of Tokyo Press, Tokyo 1985, pp. 939–940.
Dagrosa, E. E., Hajdú, P., Malerczyk, V., de Looze, S., Seeger, K., Grötsch, H. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration. Clin. Ther. 10 (1987) 18–31.
Asbach, H. W. A randomized, dose comparison study of cefodizime in the treatment of lower urinary tract infections in women. Infection 19 (1991) 85–87.
Simon, C., Stille, W. Antibiotikatherapie in Klinik und Praxis. Schattauer, Stuttgart-New York 1989, pp. 92–97.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hofstetter, A.G. Cefodizime given once daily for the treatment of upper urinary tract infections and complicated lower urinary tract infections. Infection 20 (Suppl 1), S18–S21 (1992). https://doi.org/10.1007/BF01709945
Issue Date:
DOI: https://doi.org/10.1007/BF01709945